**Question:** As per WHO classification 'X2' stage of xerophthalmia refers to:

* Core Concept: WHO classification of xerophthalmia and its stages.
* Clinical scenario: Xerophthalmia is a condition characterized by dryness and inflammation of the eyes, caused by vitamin A deficiency.

**Correct Answer: X2**

**Answer Explanation:**

The WHO classification of xerophthalmia divides the condition into five stages based on the severity of the disease. The correct answer, 'X2', refers to the second stage of xerophthalmia.

**Why the Correct Answer is Right:**

At stage X2, there is a significant reduction in the intraocular pressure, leading to a decrease in tear production. This results in the characteristic symptoms of xerophthalmia, including eye pain, photophobia, and corneal erosion. Additionally, the cornea becomes more sensitive, causing increased pain upon touch.

**Why Each Wrong Option is Incorrect:**

A. Xerophthalmia stage X1 focuses on the early stage of the condition, characterized by reduced tear secretion and mild inflammation. The symptoms of stage X1 are milder compared to stage X2.

B. Xerophthalmia stage X3 is more advanced than stage X2, with severe corneal ulceration, corneal opacity, and retinal changes, which is not present in stage X2.

C. Xerophthalmia stage X4 is another stage of the condition characterized by advanced corneal ulceration, corneal perforation, and retinal changes. In contrast, stage X2 only involves reduced tear secretion and mild inflammation, without the severe complications seen in stage X4.

D. Xerophthalmia stage X5 is the most severe stage of the condition, characterized by advanced corneal ulceration, corneal perforation, retinal detachment, and blindness. Stage X2 is less severe, involving reduced tear secretion and mild inflammation.

**Clinical Pearl:**

Xerophthalmia is a critical public health issue in developing countries, particularly among children. Early diagnosis and intervention can prevent severe complications and visual impairment. Promptly initiate vitamin A supplementation therapy for patients with stage X2 to prevent progression to more severe stages.